Akeso Reports Updated Phase III HARMONi-6 Data for Ivonescimab at ESMO Asia, Highlighting Clinical and Regulatory Momentum in China and Global Markets
Tuesday, December 09, 2025
Akeso, Inc., a Hong Kong–listed biopharmaceutical company focused on innovative biological medicines, has announced updated results from the pivotal Phase III HARMONi-6 study of its PD-1/VEGF bispecific antibody ivonescimab in combination with chemotherapy for first-line treatment of squamous non-small cell lung cancer (sq-NSCLC), presented at the 2025 ESMO Asia Congress. The data, delivered in an oral presentation by Professor Shun Lu of Shanghai Chest Hospital, underscore both statistically significant efficacy and meaningful quality-of-life advantages for patients when compared with a tislelizumab-based regimen, reinforcing ivonescimab as a competitive asset in China’s highly active immuno-oncology landscape.[2]
From a B2B and industry strategy perspective, the HARMONi-6 update is important for several reasons. First, it provides additional clinical validation for Akeso’s bispecific antibody platform, demonstrating that dual targeting of PD-1 and VEGF can translate into differentiated outcomes in a crowded checkpoint inhibitor market. Positive Phase III data in first-line sq-NSCLC, a large and high-unmet-need segment in China and broader Asia, strengthens the company’s negotiating position with partners, payers, and regulators. Second, these data come after China’s Center for Drug Evaluation (CDE) accepted a supplemental New Drug Application (sNDA) for ivonescimab combined with chemotherapy in July 2025, meaning the updated efficacy and quality-of-life findings may further support the product’s value proposition as the NMPA review advances.[2]
Quality-of-life outcomes are increasingly scrutinized by health technology assessment bodies, provincial tender committees, and hospital decision-makers in Asia. Demonstrating that ivonescimab plus chemotherapy can improve or preserve patient-reported quality-of-life measures relative to an established PD-1 regimen can influence formulary positioning, price negotiations, and inclusion in future national reimbursement discussions. For pharma executives and market access leaders, the HARMONi-6 update signals that ivonescimab may not only be competitive on traditional survival and response endpoints, but could also provide a compelling health-economic narrative around reduced symptom burden and potentially lower supportive care utilization. This is especially relevant in China’s evolving DRG and value-based procurement environment, where differentiation beyond response rate is critical.
The announcement also illustrates Akeso’s broader R&D and globalization strategy. With more than 50 innovative assets in its pipeline, including 26 clinical-stage candidates and a strong focus on bispecific and multispecific antibodies, Akeso is positioning itself as a next-generation oncology and immunology innovator from China with global aspirations.[2] Ivonescimab is one of the flagship molecules in this strategy. Beyond China, Akeso’s partner Summit Therapeutics is running the global multicenter Phase III HARMONi-3 study, which compares ivonescimab plus chemotherapy against pembrolizumab plus chemotherapy as first-line therapy in advanced NSCLC across both squamous and non-squamous histologies.[2] For global and regional business development teams, the updated HARMONi-6 results de-risk the mechanism and may increase confidence in the global program, potentially opening the door to additional territorial partnerships or co-commercialization arrangements in Asia-Pacific and other emerging markets.
For clinical development and regulatory teams, the HARMONi-6 dataset further refines the evidence base that can be leveraged in discussions with regulators in Asia beyond China. Regulators in markets such as South Korea, Southeast Asia, and potentially the Middle East often consider robust China Phase III data, especially when supported by global trials. As ESMO Asia is a major regional scientific platform, presenting these updated results there not only enhances scientific visibility but also helps build KOL advocacy across multiple Asian oncology centers. This advocacy can in turn influence clinical guideline inclusion, investigator-initiated trial activity, and the speed of uptake once approvals are secured.
The manufacturing and supply chain implications are also notable. Akeso has invested in a fully integrated GMP-compliant manufacturing system, supporting both domestic and potential export supply of biologics.[2] As ivonescimab progresses toward potential commercialization in additional indications and markets, scaling biologics production while controlling costs will be essential to compete with multinational players and domestic PD-1 incumbents. The HARMONi-6 update, by strengthening commercial visibility and likely demand projections, can inform capacity planning, technology transfer timelines with partners, and decisions on additional bioreactor deployments or CDMO engagement. For equipment and technology providers, Akeso’s trajectory presents ongoing opportunities in single-use systems, process analytics, and digital manufacturing solutions tailored to high-volume antibody production.
From an alliance and portfolio management standpoint, the ivonescimab program exemplifies a cross-border co-development model in which an innovative Chinese biologic serves as the backbone therapy for both domestic and international growth. Summit Therapeutics’ global responsibilities for HARMONi-3 illustrate how regional strengths are being combined: Akeso’s discovery and early development capabilities and local regulatory expertise in China, paired with Summit’s experience and networks in North America and other global markets. As other Asian biopharma companies evaluate their own out-licensing and co-development options, the evolution of ivonescimab’s clinical and commercial story will provide a reference case for structuring risk-sharing, milestone design, and commercialization rights in multi-regional clinical programs.
For investors and corporate strategists, the updated HARMONi-6 results come at a time when global attention on Chinese oncology innovation is intensifying. Competitive pressure in the PD-1 class has driven consolidation and price erosion in China, but differentiated mechanisms and bispecific formats are viewed as key to sustaining value. Ivonescimab’s performance in a large Phase III trial with meaningful quality-of-life benefits helps validate Akeso’s bispecific antibody platform and could influence valuation, partnership terms, and the company’s ability to access capital for later-stage programs. Moreover, by demonstrating clear clinical advantages against another PD-1–based regimen, Akeso is signaling that Chinese-origin biologics can move from fast followers to first- or best-in-class competitors, a shift with strategic implications for multinational pharma companies assessing in-licensing or M&A opportunities across Asia.
